Can voluntary pooled procurement reduce the price of antiretroviral drugs? a case study of Efavirenz

Kim, Sung Wook; Skordis‐Worrall, Jolene

doi:10.1093/heapol/czw165

Cited by 13 publications

(20 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the high prevalence of hypertension in LMICs, the scale of need is large, affording significant purchasing leverage. Pooling volumes through centralized procurement within one country or regionally between countries, as for example the PAHO strategic fund does for the PAHO region, can lead to price decreases of up to 90% across a range of medications, including cardiovascular treatments [ 21 ].…”

Section: An Ounce Of Preventionmentioning

confidence: 99%

Blood from a stone: funding hypertension prevention, treatment, and care in low- and middle-income countries

et al. 2021

View full text Add to dashboard Cite

Section: An Ounce Of Preventionmentioning

confidence: 99%

Blood from a stone: funding hypertension prevention, treatment, and care in low- and middle-income countries

et al. 2021

View full text Add to dashboard Cite

“…Empirically, much of the evidence comes from the health literature and consists of mean price comparisons and qualitative reviews of procurement systems. Contributions analyzing price changes include Kim and Skordis-Worrall (2017), who find pooled procurement by the Global Fund to reduce the price of Efavirenz by 16 to 19 percent in a differences-in-differences analysis of WHO Global price report mechanism (GPRM) data from 2004 to 2013, and Wirtz et al (2009), who find no effect of procurement volume for twelve ARVs using the same data. Seidman and Atun (2017) provide a literature review of thirty-eight papers tracked through PubMed, Embase, CINAHL and the Health Economic Evaluation Database and provide several examples of contributions concluding to cost savings from pooled procurement.…”

Section: Introductionmentioning

confidence: 99%

Pooled procurement of drugs in low and middle income countries

Dubois

Lefouili

Straub

2021

European Economic Review

View full text Add to dashboard Cite

We use data from seven low and middle income countries with diverse drug procurement systems to assess the effect of centralized procurement on drug prices, and provide a theoretical mechanism that explains this effect. Our empirical analysis is based on exhaustive data on drug sales quantities and expenditures over three years for forty important molecules. We find that centralized procurement of drugs by the public sector leads to lower prices but that the induced price reduction is smaller when the supply side is more concentrated.

show abstract

“…53 Proper management of pooled procurement increases pharmaceutical procurement efficiency and in most cases actually does reduce transaction costs. 52,55 We found that experienced intervention burden and lower opportunity costs related to the previous system influenced the acceptability of the Jazia PVS. The findings of this study are similar to those of an innovative programme which was conducted in Senegal and Vietnam to integrate the medical product supply chain for all public-sector vaccines, drugs, and other health products.…”

Section: Discussionmentioning

confidence: 92%

Acceptability of a Prime Vendor System in Public Healthcare Facilities in Tanzania

Kuwawenaruwa

Tediosi

Metta

et al. 2020

Int J Health Policy Manag

View full text Add to dashboard Cite

Background: Pharmaceutical supply chain management in low- and middle-income countries has received substantial attention to address the shortage of medicines at peripheral facilities. The focus has been on health system interventions, including the establishment of public-private partnerships (PPPs). In 2014, the United Republic of Tanzania began implementing the Jazia prime vendor system (Jazia PVS) with a contracted private wholesale supplier to complement the national medicines supply chain in public facilities. Few studies have investigated the acceptability of such a prime vendor system. This study analyses factors that contributed to the acceptability of Jazia PVS introduced in Tanzania. We used qualitative analytical methods to study experiences of Jazia PVS implementers in 4 districts in mid-2018. Methods: Data were drawn from 14 focus group discussions (FGDs), 7 group discussions (GDs) and 30 in-depth interviews (IDIs) with a range of actors involved in Jazia PVS. The study analysed 7 acceptability dimensions as defined in the acceptability framework by Sekhon et al. Framework analysis was adopted to summarise the results using a deductive and an inductive approach. Results: The findings show that participants’ acceptability of Jazia PVS was influenced by the increased availability of essential medicines at the facilities, higher order fulfilment rates, and timely delivery of the consignment. Furthermore, acceptability was also influenced by the good reputation of the prime vendor, close collaboration with district managers, and participants’ understanding that the prime vendor was meant to complement the existing supply chain. Intervention coherence, experienced opportunity cost and intervention burden, affective attitude and self-efficacy were also important in explaining the acceptability of the Jazia PVS. Conclusion: In conclusion, the most critical factor contributing to the acceptability of the Jazia PVS was the perceived effectiveness of the system in achieving its intended purpose. Districts purchasing directly from the prime vendor have a policy based on the possibility to increase availability of essential medicines at peripheral facilities in a low income setting; however, it is crucial to select a reputable and competent vendor, as well as to abide by the contractual agreements.

show abstract

Can voluntary pooled procurement reduce the price of antiretroviral drugs? a case study of Efavirenz

Cited by 13 publications

References 37 publications

Blood from a stone: funding hypertension prevention, treatment, and care in low- and middle-income countries

Blood from a stone: funding hypertension prevention, treatment, and care in low- and middle-income countries

Pooled procurement of drugs in low and middle income countries

Acceptability of a Prime Vendor System in Public Healthcare Facilities in Tanzania

Contact Info

Product

Resources

About